[Alpha Biz=(Chicago) Reporter Kim Jisun] SK Bioscience announced on the 21st that it has signed a contract with GPO, a state-run pharmaceutical company under the Thai government, to supply its own cell-cultured flu vaccine worth about 68 billion won ($ 50.68 million). The contract period is until August 18, 2033.
SK Bioscience signed a business agreement (MOU) with Thailand's GPO last month and recently signed a contract with Thailand's GPO to transfer technology for the production of SKYCELFLU.
Under the contract, SK Bioscience will be in charge of producing and commercializing Skycellflu by supplying the undiluted solution to the GPO Thai vaccine plant. The GPO will be in charge of completing the development process, including Skycellflu's permission in Thailand, and will use the vaccine for national vaccination projects.
The duration of the contract for supplying the flu vaccine undiluted solution and the amount of the contract can vary depending on market conditions and contract conditions. The actual contract period is 10 years after the release of the first licensed product in Thailand, and the contract amount is estimated based on the minimum purchase quantity and unit price. SK Bioscience explained, "It is possible to change in accordance with the agreement with the contract partner."
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
